Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | $0.78 | $0.89 | $0.83 |
Q2 2024 | 1 | $1.06 | $1.06 | $1.06 |
Q3 2024 | 3 | $1.34 | $1.35 | $1.35 |
Q4 2024 | 5 | -$2.11 | $2.89 | $1.18 |
Q1 2025 | 1 | $1.16 | $1.33 | $1.24 |
Q2 2025 | 1 | $1.34 | $1.53 | $1.43 |
Q3 2025 | 1 | $1.45 | $1.65 | $1.55 |
Q4 2025 | 1 | $1.69 | $1.94 | $1.82 |
Ligand Pharmaceuticals Incorporated last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.39 earnings per share for the quarter, missing analysts' consensus estimates of $0.75 by $1.14. The company had revenue of 51.81 M for the quarter and had revenue of 131.31 M for the year. Ligand Pharmaceuticals Incorporated has generated $3 earnings per share over the last year ($2.94 diluted earnings per share) and currently has a price-to-earnings ratio of 46.67. Ligand Pharmaceuticals Incorporated has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/08/2024 | Q3 2024 | -$0.39 | $40.60 M | $51.81 M | ||
08/07/2024 | Q2 2024 | -$2.88 | $33.04 M | $41.53 M | ||
05/08/2024 | Q1 2024 | $4.86 | $30.98 M | |||
02/29/2024 | Q4 2023 | $1.04 | $28.10 M | |||
11/09/2023 | Q3 2023 | -$0.74 | $27.22 M | $32.87 M | ||
08/09/2023 | Q2 2023 | $0.13 | $24.74 M | $26.37 M | ||
05/08/2023 | Q1 2023 | $2.46 | $43.98 M | |||
02/28/2023 | Q4 2022 | -$0.86 | $50.38 M | |||
11/08/2022 | Q3 2022 | $0.02 | $38.32 M | $66.09 M | ||
08/09/2022 | Q2 2022 | -$0.05 | $37.73 M | $57.42 M | ||
05/09/2022 | Q1 2022 | -$0.92 | $45.69 M | |||
02/28/2022 | Q4 2021 | -$0.30 | $72.47 M | |||
11/09/2021 | Q3 2021 | $1.02 | $0.82 | -0.2 | $58.74 M | $64.84 M |
08/02/2021 | Q2 2021 | $1.84 | $71.41 M | $84.68 M | ||
05/06/2021 | Q1 2021 | $1.10 | $55.15 M | |||
02/24/2021 | Q4 2020 | $0.36 | $69.99 M | |||
11/06/2020 | Q3 2020 | -$0.42 | $45.09 M | $41.85 M | ||
08/07/2020 | Q2 2020 | $1.38 | $29.96 M | $41.42 M | ||
05/08/2020 | Q1 2020 | -$1.46 | $33.16 M | |||
02/27/2020 | Q4 2019 | -$0.43 | $27.00 M |
Ligand Pharmaceuticals Incorporated has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates.
The conference call for Ligand Pharmaceuticals Incorporated's latest earnings report can be listened to online.
The conference call transcript for Ligand Pharmaceuticals Incorporated's latest earnings report can be read online.
Ligand Pharmaceuticals Incorporated (:LGND) has a recorded annual revenue of $131.31 M.
Ligand Pharmaceuticals Incorporated (:LGND) has a recorded net income of $131.31 M. Ligand Pharmaceuticals Incorporated has generated $3.02 earnings per share over the last four quarters.
Ligand Pharmaceuticals Incorporated (:LGND) has a price-to-earnings ratio of 46.67 and price/earnings-to-growth ratio is 3.04.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED